Table 1 Characteristics of the human post-mortem cases used in the study (n = 98: 26 controls, 12 AD (LATE-NC-), 55 AD(LATE-NC+), 5 FTLD-TDP). NA = non-applicable or not available. Results are displayed in mean ± standard deviation except gender and APOE frequencies
From: TDP-43 pathology is associated with increased tau burdens and seeding
Variable | Group | |||
|---|---|---|---|---|
Controls | AD(LATE-NC-) | AD(LATE-NC+) | FTLD-TDP | |
Age | 64.77 ± 9.15 | 80.42 ± 9.68 | 78.75 ± 9.97 | 61.67 ± 13.67 |
Gender frequency (m/f) | 84.6%/15.4% | 50%/50% | 43.6%/56.4% | 60%/40% |
Braak NFT Stage | 0.54 ± 0.65 | 3.50 ± 1.09 | 5.16 ± 1.08 | 0.83 ± 0.41 |
Aβ Phase | 0 | 4.60 ± 0.52 | 4.72 ± 0.69 | 0 |
LATE-NC Stage | 0.5 ± 0.82 | 0 | 2.22 ± 0.54 | NA |
Braak LBD Stage | 0.35 ± 1.23 | 0.25 ± 0.86 | 1.43 ± 2.33 | 0 |
CERAD Score | 0 | 1.17 ± 0.72 | 2.42 ± 0.74 | 0 |
CDR score | 0.17 ± 0.48 | 1.73 ± 0.90 | 2.59 ± 0.69 | 2.50 ± 0.55 |
NIA-AA score | 0 | 1.92 ± 0.51 | 2.69 ± 0.58 | 0 |
APOE ε4 frequency | 11.5% | 20% | 56.55% | 16.7% |
APOE ε2 frequency | 12% | 0% | 8.7% | NA |